Walvax Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
Walvax Biotechnology has a total shareholder equity of CN¥11.7B and total debt of CN¥712.0M, which brings its debt-to-equity ratio to 6.1%. Its total assets and total liabilities are CN¥15.0B and CN¥3.3B respectively. Walvax Biotechnology's EBIT is CN¥348.4M making its interest coverage ratio -5.5. It has cash and short-term investments of CN¥3.6B.
Key information
6.1%
Debt to equity ratio
CN¥711.96m
Debt
| Interest coverage ratio | -5.5x |
| Cash | CN¥3.62b |
| Equity | CN¥11.73b |
| Total liabilities | CN¥3.27b |
| Total assets | CN¥15.00b |
Recent financial health updates
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Jun 19
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Mar 01Recent updates
Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S
Sep 24Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Jun 19Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares
May 23There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings
Apr 07Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 02Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Mar 01Financial Position Analysis
Short Term Liabilities: 300142's short term assets (CN¥7.4B) exceed its short term liabilities (CN¥2.4B).
Long Term Liabilities: 300142's short term assets (CN¥7.4B) exceed its long term liabilities (CN¥883.7M).
Debt to Equity History and Analysis
Debt Level: 300142 has more cash than its total debt.
Reducing Debt: 300142's debt to equity ratio has increased from 0% to 6.1% over the past 5 years.
Debt Coverage: 300142's debt is well covered by operating cash flow (116.9%).
Interest Coverage: 300142 earns more interest than it pays, so coverage of interest payments is not a concern.